Takeda and TiGenix have presented 52-week data on their stem cells in Crohn’s disease patients with treatment-refractory complex perianal fistulas.

In an interview with Bloomberg published yesterday, Sage CEO Jeff Jonas was quoted as saying his company was at the top of everyone’s buying list, sending its…

Gilead has sold a phase 2-ready addiction candidate to Amygdala Neurosciences.

J&J's vet Ross has left for Henry Shein, House E&C Committee staff director Andres takes public affairs job at BIO, and Infinity's Kutok has…

In this week's EuroBiotech Report, Inventiva IPO raises €48 million for NASH trial, uniQure plots trial plan, Kitov talks fraud allegations and more.

In our EuroBiotech roundup this week, Actelion reveals financial details of spinout, Novo A/S invests in Evotec and BIAL offloads Parkinson’s drug rights.

Prima Biomed has pushed the accelerator on its in-house drug development program, pressing ahead with two trials of its immuno-oncology drug IMP321 in breast…

Juno took a major hit last year when a number of patients died in its experimental CAR-T test, which for months has remained under a cloud and another halt.…

Shares in Editas Medicine rose 30% after the U.S. patent office sided with the Broad Institute in the legal tussle over CRISPR gene editing.

Biotech